{
    "abstract": "Pulmonary hypertension (PH) is a rare, severe, and progressive pulmonary vascular disease, which includes five subgroups with similar presentation. Symptoms include dyspnea, and fatigue, and can significantly impact one's health-related quality of life (HRQL). Although treatments are mainly medical, PH group 4, chronic thromboembolic pulmonary hypertension (CTEPH), can be managed with procedures, ie pulmonary endarterectomy (PEA) and balloon pulmonary angioplasty (BPA). Currently, drugs in Europe are only approved for pulmonary arterial hypertension (PAH), and CTEPH therefore the aim of this study was to elicit novel societal health state utilities in the UK for PAH and CTEPH based on disease severity, functional class (FC), clinical events, and treatment procedures specifically for CTEPH.\nSix health states were defined: World Health Organization (WHO)-FC II, WHO-FC III, and WHO-FC IV [defined by the New York Heart Association (NYHA)]; PH-related hospitalization; and \"BPA procedure and recovery\" and \"PEA surgery and recovery\". Health states were based on a targeted literature review and two rounds of interviews with clinical experts (N = 4) and patients (N = 6). Draft health states were validated in cognitive debriefing interviews with clinical experts (N = 3). Health states were valued by the UK general public (n = 200), using a visual analogue scale (VAS) and time trade-off (TTO) assessment with the lead time method.\nThe mean TTO values/utilities were 0.81 (FC II), 0.80 (BPA), 0.78 (PEA), 0.59 (FC III), 0.28 (FC IV), and 0.25 (PH-related hospitalization). Each progression in FC was associated with worse TTO scores.\nThis study reports societal utility values for PAH and CTEPH in the UK. It provides first utility estimates for states such as BPA procedure and recovery, PEA surgery and recovery and PH-related hospitalization for this population. The results show important distinctions between FC, treatment procedures, and hospitalization, and the significant burden of disease on HRQL.",
    "authors": [
        {
            "affiliation": "Patient-Reported Outcomes, Nafees Consulting Limited, London, UK.",
            "firstname": "Beenish",
            "initials": "B",
            "lastname": "Nafees"
        },
        {
            "affiliation": "Patient-Reported Outcomes, Nafees Consulting Limited, London, UK.",
            "firstname": "Hayley M",
            "initials": "HM",
            "lastname": "de Freitas"
        },
        {
            "affiliation": "Global Market Access and Pricing, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.",
            "firstname": "Am\u00e9lie",
            "initials": "A",
            "lastname": "Beaudet"
        },
        {
            "affiliation": "Janssen Global Commercial Strategy Organization, High Wycombe, UK.",
            "firstname": "Eunju",
            "initials": "E",
            "lastname": "Todd"
        },
        {
            "affiliation": "Pulmonary Hypertension Service, Hammersmith Hospital, London, UK.",
            "firstname": "Wendy",
            "initials": "W",
            "lastname": "Gin-Sing"
        }
    ],
    "conclusions": "This study reports societal utility values for PAH and CTEPH in the UK. It provides first utility estimates for states such as BPA procedure and recovery, PEA surgery and recovery and PH-related hospitalization for this population. The results show important distinctions between FC, treatment procedures, and hospitalization, and the significant burden of disease on HRQL.",
    "copyrights": "\u00a9 2023 Nafees et al.",
    "doi": "10.2147/PPA.S400061\n10.1093/eurheartj/ehv317\n10.2174/1573403X09666131117164122\n10.3238/arztebl.2017.0073\n10.1177/2045894020977300\n10.1093/eurheartj/ehac237\n10.1183/13993003.01889\n10.1016/j.jacc.2013.10.024\n10.1016/j.jtcvs.2010.11.024\n10.1016/j.athoracsur.2012.04.004\n10.1016/j.jtcvs.2011.09.004\n10.1161/CIRCULATIONAHA.115.019470\n10.1183/16000617.0119-2016\n10.1183/09031936.00012914\n10.1183/16000617.0063-2015\n10.1176/appi.psy.51.4.339\n10.1097/jcn.0b013e318275330d\n10.1186/s12890-019-0827-5\n10.1177/1479972318787906\n10.1155/2018/3924517\n10.1007/s11136-020-02471-z\n10.2147/PPA.S160662\n10.1183/13993003.00740-2017\n10.1253/circj.CJ-16-1075\n10.21693/1933-088X-16.3.125\n10.1161/CIRCULATIONAHA.109.898122\n10.1183/13993003.00889-2017\n10.1038/sj.bjc.6603326\n10.36469/9685\n10.1016/j.lungcan.2008.03.019\n10.1185/03007991003712258\n10.1007/s10198-013-0503-2\n10.1136/bmj.316.7133.736\n10.1183/23120541.00719-2020\n10.1016/j.avsg.2018.02.019\n10.1016/j.healun.2006.11.009\n10.1056/NEJMoa1503184\n10.1056/NEJMoa1213917\n10.1002/(SICI)1099-1050(200003)9:2<149::AID-HEC501>3.0.CO;2-N\n10.1186/1465-9921-6-92\n10.1007/s40261-018-0659-8\n10.1016/j.jval.2020.12.017\n10.1007/s11136-019-02117-9",
    "journal": "Patient preference and adherence",
    "keywords": [
        "CTEPH",
        "PAH",
        "health-related quality of life",
        "hospitalization",
        "time trade-off",
        "vignette"
    ],
    "methods": null,
    "publication_date": "2023-08-31",
    "pubmed_id": "37650045\n24251459\n28241922\n33456755\n36017548\n30545971\n24355646\n21335128\n22626752\n21992851\n27052413\n28356406\n24627536\n26621976\n20587763\n23151837\n30898139\n30011997\n29750153\n32180099\n27905712\n29950821\n28775047\n28154291\n20585012\n28775050\n29950821\n16967055\n32685579\n18467000\n20225993\n23900660\n9529408\n34853780\n29678648\n17258153\n26699168\n23984728\n26113687\n10721016\n16092961\n29804184\n34119079\n30767088",
    "results": "The mean TTO values/utilities were 0.81 (FC II), 0.80 (BPA), 0.78 (PEA), 0.59 (FC III), 0.28 (FC IV), and 0.25 (PH-related hospitalization). Each progression in FC was associated with worse TTO scores.",
    "title": "A Health State Utility Study to Elicit Societal Values Associated with Pulmonary Hypertension.",
    "xml": "<Element 'PubmedArticle' at 0x788504f2f2e0>"
}